Genentech Submits Additional Lucentis Data To FDA

Label for Lucentis, pending for wet age-related macular degeneration, could include data from a Phase IIIb study supporting continuous treatment.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet